Related Experiment Video

Updated: Dec 28, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.7K

FOXM1: a potential therapeutic target in human solid cancers

Soheila Borhani1, Andrei L Gartel1

  • 1Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.

Expert Opinion on Therapeutic Targets
|February 19, 2020
PubMed

Insights

The study reviews novel targets and pathways of the FOXM1 protein, a key driver in human solid cancers. Targeting FOXM1 and its feedback loop with AKT offers new anti-cancer drug development strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Forkhead box protein M1 (FOXM1) is frequently overexpressed in human solid tumors.
  • FOXM1 plays a crucial role in cell proliferation, DNA repair, and mitosis, contributing to oncogenesis.
  • Understanding FOXM1's regulatory networks is vital for developing targeted cancer therapies.

Purpose of the Study:

  • To review novel direct transcriptional targets of FOXM1.
  • To elucidate new oncogenic pathways regulated by FOXM1.
  • To discuss the FOXM1/AKT positive feedback loop in cancer.

Main Methods:

  • Comprehensive literature review of studies published in the last 5 years.
  • Analysis of FOXM1 transcriptional targets across 16 human cancer types.
  • Examination of molecular pathways and feedback loops involving FOXM1 and AKT.

Main Results:

  • Identification of numerous FOXM1 direct transcriptional targets implicated in various cancers.
  • Elucidation of novel oncogenic mechanisms driven by FOXM1.
  • Characterization of a positive feedback loop between FOXM1 and AKT, master regulators of cancer.

Conclusions:

  • Newly identified FOXM1 targets offer alternative strategies to inhibit its pro-cancer activity.
  • Targeting the FOXM1/AKT feedback loop presents a promising dual-action approach for novel anti-cancer drug development.
  • Despite existing FOXM1 inhibitors, novel therapeutic strategies are needed due to off-target effects.
Keywords:
AKTFOXM1FOXM1/AKT loopcancertranscription

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.1K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K